FULC Q4 2021 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FULCFulcrum Therapeutics, Inc.

$436M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M+19.7% YoY

Gross Profit

-$14M-273.9% margin

Operating Income

-$24M-465.8% margin

Net Income

-$23M-464.3% margin

EPS (Diluted)

$-0.58

QoQ Revenue Growth

+2.5%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$22M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$235M

Total Liabilities

$23M

Stockholders' Equity

$212M

Cash & Equivalents

$35M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$4M	+19.7%
Gross Profit	-$14M	-$12M	-16.2%
Operating Income	-$24M	-$18M	-32.5%
Net Income	-$23M	-$18M	-32.5%